The compound medication consists of Hydroxocobalamin, Deferoxamine, and a buffer solution, which are approved by the U.S. Food and Drug Administration (FDA). Hydroxocobalamin can directly and rapidly bind with cyanide, commonly present in fire scenarios, in the respiratory system, forming the non-toxic cyanocobalamin. Deferoxamine, utilizing the company’s controlled-release technology, chelates free iron in the respiratory system, thereby reducing free radical damage. The two components complement each other and effectively prevent injuries caused by fire smoke.
Project Importance
According to statistics from the Fire Department, a total of 23,175 fire incidents occurred nationwide in 2021, resulting in 161 deaths and 1,021 injuries. Residential areas had the highest number of fire outbreaks, followed by factories and warehouses. In terms of fire losses, the total amounted to approximately NT$4.66 billion, with factories and warehouses suffering the most significant losses, accounting for around NT$1.99 billion.
The global deforestation area has continued to expand for three consecutive years. According to the latest data from the Canadian Interagency Forest Fire Centre, the cumulative burned area has exceeded 121,000 square kilometers, surpassing the land area of South Korea.
The Treatment Pathways for the OBM-B01 Combination Medication
The combination inhalation medication primarily targets the upper respiratory tract and alveoli, providing protection against toxic gases from fires. This includes Hydroxocobalamin (B12), which can neutralize cyanide, and Deferoxamine, which can reduce free radical damage.
